| 产品编号 | bs-15515R |
| 英文名称 | IFIT3 |
| 中文名称 | 干扰素诱导的三角形四肽重复蛋白3抗体 |
| 别 名 | CIG 49; CIG49; GARG 49; IFI-60K; IFI60; IFI60K; IFIT-3; IFIT-4; IFIT-3; Ifit3; IFIT3_HUMAN; IFIT4; Interferon induced 60 kDa protein; Interferon induced protein with tetratricopeptide repeats 3; Interferon-induced 60 kDa protein; Interferon-induced protein with tetratricopeptide repeats 3; Interferon-induced protein with tetratricopeptide repeats 4; IRG2; ISG-60; ISG60; P60; Retinoic acid induced gene G protein; Retinoic acid-induced gene G protein; RIG G; RIG-G; RIGG; RP11-149I23.4. |
 |
Specific References (2) | bs-15515R has been referenced in 2 publications.
[IF=4.33] Tao Yang. et al. Berberine inhibits IFN-γ signaling pathway in DSS-induced ulcerative colitis. SAUDI PHARM J. Saudi Pharm J. 2022 Apr;: WB ; Mouse.
[IF=3.448] Yang T et al. Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-γ signaling axis suppressing. Life Sci. 2020 Feb 22;248:117456. WB ; Rat.
|
| 研究领域 | 细胞生物 细胞因子 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | (predicted: Human,Mouse,Rat) |
| 产品应用 | WB=1:500-2000, IHC-P=1:100-500, IHC-F=1:100-500, ICC=1:100-500, IF=1:100-500, ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 56kDa |
| 细胞定位 | 细胞浆 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human IFIT3: 101-200/490 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 | |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
